<DOC>
	<DOC>NCT02421588</DOC>
	<brief_summary>Multicenter, open-label, randomized, controlled phase III clinical trial to evaluate the activity and safety of PM01183 versus PLD or topotecan as control arm in patients with platinum-resistant ovarian cancer. PM01183 will be explored as single agent in the experimental arm (Arm A) versus PLD or topotecan in the control arm (Arm B).</brief_summary>
	<brief_title>Clinical Trial of Lurbinectedin (PM01183) in Platinum Resistant Ovarian Cancer Patients</brief_title>
	<detailed_description />
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Topotecan</mesh_term>
	<criteria>Age &gt;/= 18 years Confirmed diagnosis of unresectable epithelial ovarian, fallopian tube or primary peritoneal cancer. Platinumresistant disease (PFI: 16 months after last platinumcontaining chemotherapy). Evaluable disease according to Response Evaluation Criteria in Solid Tumors (RECIST) v.1.1 criteria No more than three prior systemic chemotherapy regimens Eastern Cooperative Oncology Group (ECOG) performance status (PS) (ECOG PS) â‰¤ 2 Adequate hematological, renal, metabolic and hepatic function Concomitant diseases/conditions: cardiac disease, immunodeficiency, chronic active hepatitis or cirrhosis, uncontrolled infection, bowel obstruction, any other major illness Prior treatment with PM01183, trabectedin, or with both PLD and topotecan. Requirement of permanent or frequent (i.e., once per week) external drainages within two weeks prior to randomization</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>